Chief of Neurosurgical Oncology | Department of Neurosurgery | RWJMS
Professor | Department of Neurosurgery | RWJMS
Dr. Jonathan H. Sherman, MD, FAANS, FCNS, FACS, is a board-certified neurosurgeon specializing in Neurosurgical Oncology. He serves as the Chief of Neurosurgical Oncology at the Rutgers Cancer Institute of New Jersey and a Professor of Neurosurgery at Rutgers Robert Wood Johnson Medical School. Dr. Sherman obtained his medical degree from the Medical College of Georgia and completed his neurosurgery residency at the University of Virginia, followed by a fellowship in Neurosurgical Oncology at Memorial Sloan-Kettering Cancer Center.
Dr. Sherman has held prestigious positions, including Director of Neurosurgical Oncology and Stereotactic Radiosurgery at George Washington University, where he was recognized as a Washingtonian Top Doctor for five consecutive years. He then joined West Virginia University as an Associate Professor of Neurosurgery and Director of Neurosurgical Oncology for the Eastern Campus. In his current role at Rutgers, he leads a multidisciplinary team and a robust translational research program, alongside a comprehensive clinical trials program.
Dr. Sherman’s philosophy of care is rooted in his commitment to providing patient-centered, multidisciplinary treatment. He believes that the best outcomes are achieved through a collaborative approach that incorporates the most advanced treatment options available. His primary goal for patients with brain and spine tumors is to ensure they receive the highest quality care, enabling them to return to their lives with the best possible quality of life. He emphasizes the importance of a holistic treatment plan that addresses not only the medical but also the emotional and psychological needs of his patients. He is passionate about utilizing innovative treatment options and advancing neurosurgical techniques through his extensive research, which includes over 130 peer-reviewed manuscripts, a textbook on Cold Plasma Cancer Therapy, and 18 book chapters.
His extensive education and training include a fellowship in Surgical Neuro-oncology at Memorial Sloan-Kettering Cancer Center and comprehensive training at the University of Virginia, where he completed his residency and fellowship in neurosurgery. He has also trained internationally at Auckland City Hospital in New Zealand, adding a global perspective to his expertise.
Dr. Sherman’s clinical areas of interest are diverse and cutting-edge. He is skilled in stereotactic radiosurgery using both Gamma Knife and LINAC-based techniques, fluorescence-guided neurosurgery, and advanced neuromodulation techniques. He is particularly passionate about developing and implementing neuro-oncology clinical trials, striving to push the boundaries of current treatments and discover innovative solutions for complex neurological conditions.
Throughout his career, Dr. Sherman has held numerous prestigious positions, including Director of Surgical Neuro-oncology at George Washington University and West Virginia University’s Rockefeller Neuroscience Institute. His dedication to advancing the field is evident in his significant contributions to translational research, aiming to bridge the gap between laboratory discoveries and clinical applications. His work on cold plasma technology for cancer treatment and numerous other research projects has been recognized and funded by esteemed institutions like the National Science Foundation and the Charlie Teo Foundation.
Dr. Sherman’s passion for neurosurgery extends beyond his clinical practice. He is an avid researcher with a focus on improving clinical outcomes for patients undergoing radiosurgery and other advanced treatments. He has published extensively in leading neurosurgical journals and contributed to numerous peer-reviewed articles and book chapters, sharing his expertise with the broader medical community.
A national and international expert in neuro-oncology, Dr. Sherman is a member of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), serving on the AANS/CNS Joint Tumor Section Executive Committee for nine years. He is an Academic Editor for PLoS-One and an Associate Editor for Operative Neurosurgery. He is also a Fellow of the AANS, CNS, and the American College of Surgeons.
Dr. Sherman’s work as a clinician-scientist involves translational research aimed at directly impacting and advancing treatments for his patients. He is a pioneer in using healthcare innovations, such as virtual and augmented reality, to improve patient outcomes. Beyond his clinical and research contributions, Dr. Sherman is deeply passionate about mentoring and educating the next generation of neurosurgeons at Rutgers University. His dedication to mentorship and education is evident through his guidance of numerous medical students and residents, as well as his involvement in various educational and research initiatives, including virtual reality enhancements for anatomy education and innovative cancer pilot research studies. This commitment reflects his unwavering dedication to fostering future leaders in neurosurgery and advancing the field through cutting-edge education and research.
Dr. Jonathan H. Sherman is driven by his passion for improving patient care and advancing the field of neurosurgery. His holistic approach, combining cutting-edge research with compassionate patient care, ensures that his patients receive the best possible treatment tailored to their individual needs. His unwavering dedication to his patients, passion for advancing neurosurgical techniques, and commitment to education and research make him a distinguished leader in the field of neurosurgery.
__________________________________________________________________
Education:
Medical School:
Medical College of Georgia, Augusta, Georgia
Doctor of Medicine, 2003
Residency:
University of Virginia, University Hospital,
Department of Neurological Surgery, Chief Resident, 2009 – 2010
Fellowship:
Memorial Sloan-Kettering Cancer Center, Department of Neurological Surgery
Surgical Neuro-oncology Fellow, 2010 – 2011
Board Certification:
American Board of Neurological Surgery
__________________________________________________________________
Awards:
- Maryland Magazine Top Surgeon 2021
- WVU Office of Global Affairs Virtual Exchange Award – February 2021
- AANS/CNS Section on Tumors – Executive Committee – October 2013 – Present
- Fellow of the American College of Surgeons – July 2017 – Present
- Washingtonian Top Docs 2015 -2019
- Journal of Neuro-oncology Top Reviewer – 2014
- AOA Honor Medical Society – October 2002
- Reagents Opportunity Scholarship – 2000 – 2001
- Dean’s Student Research Fellow – Summer 2000
- Reagents Opportunity Scholarship – 1999 – 2000
- Peacock Family Award for outstanding performance in gross anatomy – 1999
__________________________________________________________________
Clinical Areas of Interest:
- Surgical management of brain and spinal tumors; stereotactic radiosurgery (Gamma Knife and LINAC-based); fluorescence-guided neurosurgery; laser-interstitial thermal therapy (LITT); intraoperative awake/cortical mapping; neuro-oncology clinical trial development and implementation.
__________________________________________________________________
Publications:
Theranostic Potential of Novel Adaptive Cold Atmospheric Plasma With Temozolomide To Checkmate Glioblastoma: An In Vitro Study. Soni V, Adhikari M, Lin L, Sherman JH, Michael, Keidar M., Cancers. In Press.
A Consensus Definition of Supratotal Resection for Anatomically Distinct Primary Glioblastoma: An AANS/CNS Section on Tumors Survey of Neurosurgical Oncologists. Rakovec M, Khalafallah AM, Wei O, Day D, Sheehan JP, Sherman JH, D Mukherjee., J Neurooncol. In Press.
Cold plasma discharge tube enhances anti-tumoral efficacy of temozolomide. Yao X, Yan D, Lin L, Sherman JH, Peters KB, Keir ST, Keidar M., ACS Applied Bio Mater. 2022, 5, 4, 1610–1623.
Malignant primary parenchymal tumors in adults: a national cancer database analysis. Chalif EJ, Mozaffari K, Chillakuru YR, Shim T, Monfared A, Murray RD, Sherman JH., Neurosurg. June 2022 – Volume 90 – Issue 6 – p 807-815
Update on the role of cytoreductive surgery in the management of progressive glioblastoma., J Patrick H, Sherman JH, Elder N, Olson JJ., J Neurooncol. 2022 Jun;158(2):167-177.
Rapidly Recurrent Recalcitrant Rathke’s Cleft Cyst: Case report and review of the literature., Chalif EJ, Shatanofy ME, Mozaffari K, Sherman JH., Neurochirurgie. 2022 Mar 5:S0028-3770(22)00012-1.
5-aminolevulinic acid for enhanced surgical visualization of high-grade glioma: a prospective multi-center study. Schupper AJ, Baron RB, Cheung W, Rodriguez J, Kalkanis S, Chohan M, Anderson B, Chamoun R, Nahed B, Zacharia B, Kennedy J, Moulding HD, Zucker L, Chicoine M, Olsen J, Jenson R, Sherman JH, Zhang X, Price G, Fowkes F, Germano I, Carter BS, Hadjipanayas CG, J Neurosurg. 2021 Oct 8;1-10.
Next-Generation Simulation – Integrating Extended Reality Technology into Medical Education., Herur-Raman A, Almeida ND, Greenleaf W, Williams D, Karshenas A, Sherman JH., Front Virtual Real. 2021 Sept 7. Volume 2.
Multi-modal Biological Destruction by Cold Atmospheric Plasma: Capacity and Mechanism., Yan D, Malyavko A, Wang Q, Sherman JH, Ostrikov K, Keidar M., Biomedicines 2021, 9(9), 1259.
In vitro & in vivo sensitization of human glioblastoma to temozolomide by cold atmospheric plasma., Soni V, Adhikari M, Simonyan H, Yao X, Lin L, Sherman JH, Young C, Keidar M., Cancers 2021, 13(17), 4485.
__________________________________________________________________
Location:
Robert Wood Johnson University Hospital New Brunswick Ambulatory Pavilion
10 Plum Street – 5th Floor
New Brunswick, NJ 08901